Histochemical approaches to assess cell-to-cell transmission of misfolded proteins in neurodegenerative diseases

European Journal of Histochemistry

Volumn 57, Issue 1, 2013, Pages 31-35

  Natale, G ^a   Pompili, E ^b   Biagioni, F ^c   Paparelli, S ^a   Lenzi, P ^a   Fornai, F ^a,c  

^a UNIVERSITY OF PISA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

Author keywords

Advanced glycation end products; Exosome; Neurodegenerative diseases; Prion diseases; Prionoids; RAGEs; Synucleinopathies

Indexed keywords

ADVANCED GLYCATION END PRODUCT;

ANIMAL; CELL COMMUNICATION; DEGENERATIVE DISEASE; HUMAN; METABOLISM; MORTALITY; PATHOGENICITY; PATHOLOGY; PRION; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCY; REVIEW;

ANIMALS; CELL COMMUNICATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; METABOLISM; MORTALITY; NEURODEGENERATIVE DISEASES; PATHOGENICITY; PATHOLOGY; PRIONS; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES;

EID: 84875014167     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/ejh.2013.e5     Document Type: Article

References (64)

1. Lach B, Grimes D, Benoit B, Minkiewicz- Janda A. Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material. Acta Neuropathol 1992;83:352-60.
2. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopaminealpha- synuclein adduct. Science 2001;294: 1346-9.
3. Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol 2008;65: 184-9.
4. Natale G, Pasquali L, Paparelli A, Fornai F. Parallel manifestations of neuropathologies in the enteric and central nervous systems. Neurogastroenterol Motil 2011; 23:1056-65.
5. Natale G, Ferrucci M, Lazzeri G, Paparelli A, Fornai F. Transmission of prions within the gut and towards the central nervous system. Prion 2011;5:142-9.
6. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-40.
7. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol 2001;58:186-90.
8. Jellinger KA. Neuropathological spectrum of synucleinopathies. Mov Disord 2003;18: S2-12.
9. Rusina R, Kovacs GG, Fiala J, Hort J, Ridzo P, Holmerová I, et al. FTLD-TDP with motor neuron disease, visuospatial impairment and a progressive supranuclear palsy-like syndrome: broadening the clinical phenotype of TDP-43 proteinopathies. A report of three cases. BMC Neurol 2011;11:50.
10. Charles V, Mezey E, Reddy PH, Dehejia A, Young TA, Polymeropoulos MH, et al. Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models. Neurosci Lett 2000;289:29-32.
11. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and otherneurodegenerative disorders. Ann Neurol. 2011;70:532-40.
12. Polymenidou M, Cleveland DW. The seeds of neurodegeneration: prion-like spreading in ALS. Cell 2011;147:498-508.
13. Martin LJ. Transgenic mice with human mutant genes causing Parkinson's disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. Rev Neurosci 2007;18:115-36.
14. Steiner JA, Angot E, Brundin P. A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ 2011;18: 1425-33.
15. Gilbert RM, Fahn M, Mitsumoto H, Rowland LP. Parkinsonism and motor neuron diseases: twenty-seven patients with diverse overlap syndromes. Mov Disord 2010;25: 1868-5.
16. Vivacqua G, Casini A, Vaccaro R, Salvi EP, Pasquali L, Fornai F, et al. Spinal cord and parkinsonism: neuromorphological evidences in humans and experimental studies. J Chem Neuroanat 2011;42:327-40.
17. Vivacqua G, Biagioni F, Yu S, Casini A, Bucci D, D'Este L, et al. Loss of spinal motor neurons and alteration of alphasynuclein immunostaining in MPTP induced Parkinsonism in mice. J Chem Neuroanat 2012;44:76-85.
18. Corrochano S, Renna M, Tomas-Zapico C, Brown SD, Lucas JJ, Rubinsztein DC,et al. α-Synuclein levels affect autophagosome numbers in vivo and modulate Huntington disease pathology. Autophagy 2012;8:431-32.
19. Shults CW. Lewy bodies. Proc Natl Acad Sci USA 2006;103:1661-8.
20. Campbell BC, McLean CA, Culvenor JG, Gai WP, Blumbergs PC, Jäkälä P, et al. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. J Neurochem 2001;76:87-96.
21. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-73.
22. Coppedè F. Genetics and epigenetics of Parkinson's disease. Scientific World Journal 2012;2012:489830.
23. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Capobianco L, et al. Similarities between methamphetamine toxicity and proteasome inhibition. Ann N Y Acad Sci 2004;1025:162-70.
24. Williams A, Jahreiss L, Sarkar S, Saiki S, Menzies FM, Ravikumar B, et al. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr Top Dev Biol 2006;76: 89-101.
25. Rubinsztein DC, Cuervo AM, Ravikumar B, Sarkar S, Korolchuk V, Kaushik S, et al. In search of an "autophagomometer". Autophagy 2009;5:585-9.
26. Hanna RA, Quinsay MN, Orogo AM, Giang K, Rikka S, Gustafsson AB. Microtubuleassociated Protein 1 Light Chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy. J Biol Chem 2012;287:19094-104.
27. Castino R, Lazzeri G, Lenzi P, Bellio N, Follo C, Ferrucci M, et al. Suppression of autophagy precipitates neuronal cell death following low doses of methamphetamine. J Neurochem 2008;106:1426-39.
28. Vicente MH, Outeiro TF. The sour side of neurodegenerative disorders: The effects of protein glycation. J Pathol 2010;221:13-25.
29. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009;64:783-90.
30. Ticozzi N, Silani V, LeClerc AL, Keagle P, Gellera C, Ratti A, et al. Analysis of FUS gene mutation in familial amyotrophic lateral sclerosis within an Italian cohort. Neurology 2009;73:1180-5.
31. Fornai F, Meininger V, Silani V. Future therapeutical strategies dictated by preclinical evidence in ALS. Arch Ital Biol. 2011;149:169-74.
32. Grillo MA, Colombatto S. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids. 2008;35:29-36.
33. Li J, Liu D, Sun L, Lu Y, Zhang Z. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci. 2012;317:1-5.
34. Fernagut PO, Hutson CB, Fleming SM, Tetreaut NA, Salcedo J, Masliah E, et al. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 2007;61:991-1001.
35. Haritani M, Spencer YI, Wells GA. Hydrated autoclave pretreatment enhancement of prion protein immunoreactivity in formalin- fixed bovine spongiform encephalopathy- affected brain. Acta Neuropathol 1994;87:86-90.
36. Rosicarelli B, Serafini B, Sbriccoli M, Lu M, Cardone F, Pocchiari M, et al. Migration of dendritic cells into the brain in a mouse model of prion disease. J Neuroimmunol 2005;165:114-20.
37. Takahashi RH, Tobiume M, Sato Y, Sata T, Gouras GK, Takahashi H. Accumulation of cellular prion protein within dystrophic neurites of amyloid plaques in the Alzheimer's disease brain. Neuropathology. 2011;31:208-14.
38. Rahman S, Arai S, Saijo S, Yamato I, Murata T. Sarkosyl is a good regeneration reagent for studies on vacuolar-type ATPase subunit interactions in Biacore experiments. Anal Biochem 2011;418:301-3.
39. Emmanouilidou E, Melachroinou K, Roumeliotis, Garbis SD, Ntzouni M, Margaritis LH, et al. Cell produced alfasynuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J. Neurosci 2010;30:6838-51.
40. Fornai F, Lenzi P, Gesi M, Ferrucci M, Lazzeri G, Natale G, et al. Recent knowledge on molecular components of Lewy bodies discloses future therapeutic strategies in Parkinson's disease. Curr Drug Targets CNS Neurol Disord 2003;2:149-52.
41. Lenzi P, Fulceri F, Lazzeri G, Casini A, Ruggieri S, Paparelli A, et al. Analysis of single, purified inclusions as a novel approach to understand methamphetamine neurotoxicity. Ann N Y Acad Sci 2008;1139:186-90.
42. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci USA 2006;10:4246-51.
43. Mauceli G, Busceti CI, Pellegrini A, Soldani P, Lenzi P, Paparelli A, et al. Overexpression of alpha-synuclein following methamphetamine: is it good or bad? Ann N Y Acad Sci 2006;1074:191-7.
44. Fornai F, Soldani P, Lazzeri G, di Poggio AB, Biagioni F, Fulceri F, et al. Neuronal inclusions in degenerative disorders Do they represent static features or a key to understand the dynamics of the disease? Brain Res Bull 2005;65:275-90.
45. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alphasynuclein. Proc Natl Acad Sci USA 2009;106:13010-5.
46. Angot E, Steiner JA, Lema Tomé CM, Ekström P, Mattsson B, Björklund A, et al. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 2012;7:e39465.
47. Koch M, Chitayat S, Dattilo BM, Schiefner A, Diez J, Chazin WJ, et al. Structural basis for ligand recognition and activation of RAGE. Structure 2010;18:1342-52.
48. Chen L, Wei Y, Wang X, He R. Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 2010;5:e9052.
49. Lue LF, Walker DG, Brachova L, Yan SD. Involvement of microglial receptor for advanced glycation endproducts (rage) in alzheimer's disease: Identification of a cellular activation mechanism Exp Neurol 2001;17:29-45.
50. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, et al. Immuno - histochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease Brain Res 2001;888: 256-262.
51. Zlokovic B.V. New therapeutic targets in the neurovascular pathway in Alzheimer's disease Neurotherapeutics 2008;5:409-414.
52. Maliska D, Laure-Kamionowska M, Taraszewska A, Dergowski K, Maliski S. Immunodistribution of amyloid beta protein (Aβ) and advanced glycation end-product receptors (RAGE) in choroid plexus and ependyma of resuscitated patients. Folia Neuropathol 2011;49:295-300.
53. Askarova S, Yang X, Sheng W, Sun GY, Lee JC. Role of Aβ-receptor for advanced glycation endproducts interaction in oxidative stress and cytosolic phospholipase Aβ activation in astrocytes and cerebral endothelial cells. Neuroscience 2011;199:375-85.
54. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
55. Casula M, Iyer AM, Spliet WG, Anink JJ, Steentjes K, Sta M, et al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 2011;179:233-43.
56. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992;267:14998-5004.
57. Chivet M, Hemming F, Pernet-Gallay K, Fraboulet S, Sadoul R. Emerging role of neuronal exosomes in the central nervous system. Front Physiol 2012;3:145.
58. Gousset K, Zurzolo C. Tunnelling nanotubes: a highway for prion spreading? Prion 2009;3:94-8.
59. Ahmed KA, Xiang J. Mechanisms of cellular communication through intercellular protein transfer. J Cell Mol Med 2011;15: 1458-73.
60. Yamasaki T, Suzuki A, Shimizu T, Watarai M, Hasebe R, Horiuchi M. Characte-rization of intracellular localization of PrP(Sc) in prion-infected cells using a mAb that recognizes the region consisting of aa 119-127 of mouse PrP. J Gen Virol 2012;93:668-80.
61. Santa-Maria I, Varghese M, Ksiezak-Reding H, Dzhun A, Wang J, Pasinetti GM. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of tau protein in aggresomes. J Biol Chem 2012;287:20522-33.
62. Vella LJ, Sharples RA, Nisbet RM, Cappai R, Hill AF. The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J 2008;37:323-32.
63. Fevrier B, Vilette D, Archer F, Loew D, Faigle W, Vidal M, et al. Cells release prions in association with exosomes. Proc Natl Acad Sci USA 2004;101:9683-8.
64. Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, et al. Alzheimer's disease amyloid peptides are released in association with exosomes. Proc Natl Acad Sci USA 2006;103:11172-77.